Home » Topics » Regulatory » EMA

EMA
RSS

EMA recommends Cell Therapeutics submit revised PIP for pixantrone

April 22, 2010

European Joulferon MAA for chronic hepatitis C withdrawn

April 21, 2010

Aeterna Zentaris receives advice from the EMA for phase III perifosine program

April 16, 2010

Raloxifene decreases epistaxis in hereditary hemorrhagic telangiectasia / News in Context

April 13, 2010

EMA grants orphan drug designation to Protalix's taliglucerase alfa for Gaucher's disease

March 30, 2010

Bioalliance Pharma's antiemetic Setofilm approved in Europe

March 30, 2010

European Commission approves DuoPlavin/DuoCover dual antiplatelet combination tablet

March 26, 2010

EMA accepts Cinryze MAA for hereditary angioedema for filing

March 25, 2010

EMA completes validation of InterMune's pirfenidone MAA for IPF

March 24, 2010

FDA and EMA respond to GSK's report on rotavirus DNA in Rotarix vaccine

March 24, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...